In an adult with psoriatic arthritis who is taking tofacitinib (Xeljanz) 5 mg twice daily and methotrexate 20 mg weekly without adequate symptom control, what is the next appropriate therapeutic step?

Switch to a TNF Inhibitor Biologic

For a patient with psoriatic arthritis inadequately controlled on tofacitinib 5 mg twice daily plus methotrexate 20 mg weekly, the next step is to switch to a TNF inhibitor biologic (such as adalimumab, etanercept, or infliximab), preferably as monotherapy. 1

Rationale for This Recommendation

The 2018 ACR/NPF guidelines specifically address this clinical scenario—active PsA despite oral small molecule (OSM) therapy. The guidelines conditionally recommend switching to a TNF inhibitor over other options including IL-17 inhibitors, IL-12/23 inhibitors, or another oral small molecule. 1 This recommendation is based on low-to-moderate quality evidence but represents the consensus approach for escalating therapy after OSM failure.

Key Decision Points

Tofacitinib is classified as an oral small molecule (OSM), not a biologic DMARD. When patients fail OSM therapy:

• First-line biologic choice: TNF inhibitor over IL-17i, IL-12/23i, abatacept, or switching to another OSM 1
• Biologic monotherapy is preferred over biologic + methotrexate combination for most biologics 1
• The exception: if initiating a TNF inhibitor monoclonal antibody (adalimumab, infliximab, golimumab), continuing methotrexate may reduce immunogenicity and improve therapeutic maintenance 2, 3

Alternative Considerations

The guidelines acknowledge situations where alternatives may be appropriate 1:

• IL-17 or IL-12/23 inhibitors if severe psoriasis dominates the clinical picture
• Continue with another OSM or tofacitinib if contraindications to TNF inhibitors exist (recurrent infections, congestive heart failure, demyelinating disease)
• Abatacept if recurrent serious infections are a concern
• IL-12/23 inhibitor if concomitant inflammatory bowel disease is present

Methotrexate Continuation Decision

If you choose a TNF inhibitor monoclonal antibody (adalimumab, infliximab, golimumab), consider continuing methotrexate to reduce immunogenicity and maintain therapeutic response, despite lack of evidence for superior short-term efficacy. 1, 2, 3

If you choose etanercept (TNF receptor fusion protein), IL-17 inhibitor, IL-12/23 inhibitor, or IL-23 inhibitor, you can discontinue methotrexate after confirming the new biologic's efficacy, as these agents show minimal benefit from combination therapy and have lower immunogenicity. 1, 4, 2

Dosing Considerations for Tofacitinib

Before switching, verify the patient is on adequate tofacitinib dosing. The FDA-approved dose for PsA is 5 mg twice daily, which this patient is receiving. 5 While 10 mg twice daily shows greater efficacy, it carries higher risks of infection and cytopenia and is not FDA-approved for PsA. 6, 5 Given the patient has failed at the standard dose, escalating tofacitinib is not the recommended approach—switching drug classes is preferred.

Safety Monitoring During Transition

When transitioning from tofacitinib to a biologic:

• Do not combine tofacitinib with biologics—this combination is explicitly not recommended due to increased immunosuppression risk 1, 5, 7
• Tofacitinib can be stopped abruptly when starting the biologic
• If continuing methotrexate with a TNF inhibitor mAb, this may provide therapeutic "bridge" during the transition 1

Common Pitfalls to Avoid

1. Don't combine tofacitinib with biologics: Despite emerging case reports of dual therapy 7, 8, current guidelines strongly recommend against this due to safety concerns and lack of efficacy data
2. Don't assume methotrexate must continue: Unlike in rheumatoid arthritis, combination therapy in PsA shows limited benefit except for reducing immunogenicity of TNF inhibitor mAbs 4, 2, 3
3. Don't delay switching: The GRAPPA 2021 guidelines support early escalation to biologics (12-24 weeks) when conventional therapy fails, and recent evidence suggests TNF inhibitors may be superior to csDMARDs as first-line therapy 4

Subsequent Steps if TNF Inhibitor Fails

Should the patient fail the first TNF inhibitor, the 2018 ACR/NPF guidelines recommend 1:

• Switch to a different TNF inhibitor (preferred over switching to IL-17i, IL-12/23i, abatacept, or tofacitinib)
• Consider IL-17 inhibitor if severe psoriasis is present or if primary TNF inhibitor failure occurred
• Consider IL-12/23 inhibitor if inflammatory bowel disease develops or patient prefers less frequent dosing

The 2024 EULAR guidelines provide similar recommendations, emphasizing that switching within or between biologic classes is appropriate after inadequate response. 9